uploads///MON Analysts NTM Recommendation and Target

Analyst Ratings and Price Target for Monsanto in August 2017


Aug. 22 2017, Updated 9:36 a.m. ET


Monsanto (MON) stock continues to deliver a favorable performance among other agribusiness stocks (XLB) so far this year. It has risen 11.0% YTD (year-to-date), outperforming the S&P 500, which has risen 8.0%. As the company waits to be merged with Bayer, its stock price is gradually climbing to $128, which is the deal price.

Article continues below advertisement

Analyst ratings

As of August 18, 2017, the mean consensus analyst rating for Monsanto (MON) stock was 2.5 with a “buy” recommendation for the next 12-month period. Of the 18 analysts surveyed by Reuters, two have a “strong buy” recommendation on the stock for the next 12 months.

We can see in the above graph that the most recent analyst recommendations show one more analyst with a “buy” recommendation, taking the total to six “buy” recommendations. Thus the number of analysts recommending a “hold” is one less, or ten analysts.

Unlike fertilizer companies (MXI) such as PotashCorp (POT), CF Industries (CF), and Mosaic (MOS), Monsanto doesn’t have any “sell” or “strong sell” ratings.

Price target

The consensus mean price target for Monsanto (MON) is $124 as of August 18, 2017. However, the median price target is $128, which is Monsanto’s acquisition price. That’s almost 7.0% higher than the closing price of $116.80 on August 18. However, when compared with the median price target, there’s an upside of almost 9.5%.

Next, let’s look at FMC (FMC).


More From Market Realist